Predictive value of serial measurements of quality of life on all-cause mortality in prostate cancer patients: data from CaPSURE (cancer of the prostate strategic urologic research endeavor) database.
BACKGROUND
Health-related quality of life (HRQOL) is a legitimate construct for evaluating treatment and its side effects. Recently, predictive value of HRQOL on survival also has been of interest. In light of the longer survival in patients with prostate cancer and importance of quality of life, we seek to evaluate the association between HRQOL and survival using traditional and novel techniques.


METHODS
Patients from CaPSURE (Cancer of the Prostate Strategic Urologic Research Endeavor) who were treated within 6 months of diagnosis and had pre-treatment and sufficient post-treatment follow-up information constituted the study population. A sample consisting of 2,899 patients met the study criteria. SF-36 domains were used to measure HRQOL outcomes. Categorical variables were created for HRQOL based on the baseline distribution of the lower 10th percentile and the remainder of the patients. Association between HRQOL and survival (defined by all-cause mortality) in patients with prostate cancer was evaluated using Cox proportional hazards models controlling for age at diagnosis, type of treatment received, clinical risk classification, and number of comorbidities. Sequential bootstrap resampling was implemented to evaluate stability of the model. Univariate and multivariate Cox proportional hazards models were fit using various time points over the course of follow-up.


RESULTS
In the analysis looking at association of HRQOL baseline measurements, higher levels of physical function and general health were significantly associated with better survival (HR 0.49 95% CI 0.32-0.78 and HR 0.51 95% CI 0.35-0.75, respectively). Post-treatment analysis demonstrated similar results. In time-dependent analysis, higher levels of physical function, role physical, and general health were significantly associated with better survival (HR ranged from 0.57 to 0.65). In addition, analysis looking at change in HRQOL scores demonstrated an association between higher scores on physical function, role physical, vitality, social function, and general health and longer survival (HR ranged from 0.56 to 0.63).


CONCLUSIONS
This study demonstrated that several domains of HRQOL were significantly associated with survival in a large group of patients with localized prostate cancer. This association was maintained over the course of disease regardless of the time of the assessment. Results from our study have both research and clinical relevance. They could provide information that enable us to not only improve communication with patients and families, but also to develop interventions and treatments best suited for the patient.
Sadetsky
Natalia
N
UCSF, San Francisco, CA, USA. nsadetsky@urology.ucsf.edu
Hubbard
Alan
A
Carroll
Peter R
PR
Satariano
William
W
D000368:Aged; D016001:Confidence Intervals; D016208:Databases, Factual; D006305:Health Status Indicators; D006306:Health Surveys; D006801:Humans; D008297:Male; D008875:Middle Aged; D009026:Mortality / Q000639:trends; D015999:Multivariate Analysis; D011237:Predictive Value of Tests; D016016:Proportional Hazards Models; D011471:Prostatic Neoplasms / Q000175:diagnosis* / Q000401:mortality; D011594:Psychometrics; D011788:Quality of Life; D016019:Survival Analysis; D013997:Time Factors; D014481:United States
Arch Gerontol Geriatr. 2009 Jan-Feb;48(1):14-8
17950481
Gerontologist. 2005 Apr;45(2):216-21
15799986
J Clin Oncol. 2003 May 1;21(9):1660-8
12721239
Eur J Cancer. 2005 Apr;41(6):922-31
15808958
J Clin Oncol. 2004 Oct 1;22(19):3877-85
15459209
Qual Life Res. 2004 Sep;13(7):1209-16
15473499
JAMA. 1995 Jan 11;273(2):129-35
7799493
J Clin Oncol. 2003 Feb 15;21(4):673-8
12586805
Annu Rev Public Health. 1999;20:145-57
10352854
Cancer. 2004 Jan 15;100(2):425-32
14716781
Qual Life Res. 2006 Oct;15(8):1297-306
16830258
Eur J Cancer. 2004 May;40(7):1021-30
15093577
J Gerontol B Psychol Sci Soc Sci. 2001 Jul;56(4):S195-205
11445612
Annu Rev Public Health. 2001;22:91-113
11274513
Cancer. 1999 Jan 15;85(2):333-40
10023700
Urology. 1996 Nov;48(5):773-7
8911524
J Clin Oncol. 2004 Aug 15;22(16):3381-8
15310784
Curr Urol Rep. 2004 Jun;5(3):166-72
15161564
Int J Radiat Oncol Biol Phys. 2004 Apr 1;58(5):1394-404
15050315
Stat Med. 1992 Dec;11(16):2093-109
1293671
Stat Med. 2002 Dec 30;21(24):3865-84
12483772
J Clin Oncol. 2000 Nov 15;18(22):3768-74
11078489
Cancer. 2007 May 1;109(9):1777-83
17354226
Support Care Cancer. 2007 Apr;15(4):387-93
17093913
Cancer. 2002 Jul 15;95(2):281-6
12124827
J Am Geriatr Soc. 2003 Jan;51(1):63-8
12534847
Kidney Int. 2006 Aug;70(4):771-80
16820797
Med Care. 1992 Jun;30(6):473-83
1593914